Total Funding
17
43
Total FundingSeries B raised
Growth Score
-8 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
62863
Transforming heart failure treatment with the world’s first in-heart microcomputer
Amit Gilon: InvestorPast Role: Ginger Software, SVP Business Development
About the Company
Vectorious Medical Technologies developed the V-LAP, the worlds first in-heart microcomputer which enables optimal treatment for heart failure patients, increasing their quality of life and life expectancy. The V-LAP sensory implant is the first digital, wireless, battery-less device that is able to communicate from deep within the body. It
monitors the heart’s left atrium pressure (LAP) which has been proven to be the earliest, most accurate and effective predictor for heart failure deterioration. Vectorious is actively conducting clinical studies in Europe (Italy, Germany, UK and Israel) for the purpose of obtaining a CE mark. It is expected to launch a clinical study in the US in 2020.
